How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,523 results for

Alpha Adrenergic Antagonist

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Proceedings: Is thymoxamine a specific alpha-adrenoceptor blocking agent? Full Text available with Trip Pro

Proceedings: Is thymoxamine a specific alpha-adrenoceptor blocking agent? 4148921 1974 02 27 2018 11 13 0007-1188 44 2 1972 Feb British journal of pharmacology Br. J. Pharmacol. Proceedings: Is thymoxamine a specific alpha-adrenoceptor blocking agent? 362P-362P Fawke L L eng Journal Article England Br J Pharmacol 7502536 0007-1188 0 Adrenergic alpha-Antagonists 0 Receptors, Adrenergic 1WS297W6MV Phenylephrine PW8QYA7KI0 Moxisylyte Z468598HBV Phentolamine IM Adrenergic alpha-Antagonists Animals (...) Electric Stimulation Guinea Pigs Hypogastric Plexus drug effects In Vitro Techniques Male Moxisylyte pharmacology Muscle Contraction drug effects Phentolamine pharmacology Phenylephrine pharmacology Receptors, Adrenergic drug effects Vas Deferens drug effects physiology 1972 2 1 1972 2 1 0 1 1972 2 1 0 0 ppublish 4148921 PMC1666072 Br J Pharmacol Chemother. 1963 Dec;21:569-80 14110756 J Pharm Pharmacol. 1965 Jul;17(7):449-58 4379268 J Physiol. 1956 Mar 28;131(3):678-89 13320365

1972 British journal of pharmacology

102. Relative affinities of some alpha-adrenoceptor blocking drugs in isolated human smooth muscle. Full Text available with Trip Pro

Relative affinities of some alpha-adrenoceptor blocking drugs in isolated human smooth muscle. 4395086 1971 02 04 2018 11 13 0007-1188 40 1 1970 Sep British journal of pharmacology Br. J. Pharmacol. Relative affinities of some alpha-adrenoceptor blocking drugs in isolated human smooth muscle. 155P-157P Coupar I M IM Turner P P eng Journal Article England Br J Pharmacol 7502536 0007-1188 0 Adrenergic alpha-Antagonists 0 Aniline Compounds 0 Dibenzazepines 0 Hydroquinones 0 Imidazoles 0 (...) Sympatholytics CHH9H12AQ3 Tolazoline Z468598HBV Phentolamine IM Adrenergic alpha-Antagonists pharmacology Aniline Compounds pharmacology Dibenzazepines pharmacology Humans Hydroquinones pharmacology Ileum drug effects Imidazoles pharmacology In Vitro Techniques Muscle, Smooth drug effects Phentolamine pharmacology Saphenous Vein drug effects Sympatholytics pharmacology Tolazoline pharmacology 1970 9 1 1970 9 1 0 1 1970 9 1 0 0 ppublish 4395086 PMC1702676 J Pharm Pharmacol. 1965 Jul;17(7):449-58 4379268 Br J

1970 British journal of pharmacology

103. Antagonism by (+)-amphetamine of the inhibition of [3H]-noradrenaline overflow obtained by alpha-adrenoceptor agonists or bretylium in the perfused cat spleen [proceedings] Full Text available with Trip Pro

C eng Journal Article England Br J Pharmacol 7502536 0007-1188 0 Adrenergic alpha-Agonists 0 Bretylium Compounds TZ47U051FI Dextroamphetamine X4W3ENH1CV Norepinephrine IM Adrenergic alpha-Agonists antagonists & inhibitors Animals Bretylium Compounds antagonists & inhibitors Cats Dextroamphetamine pharmacology In Vitro Techniques Norepinephrine metabolism Spleen drug effects metabolism 1979 7 1 1979 7 1 0 1 1979 7 1 0 0 ppublish 43177 PMC2043685 Rev Physiol Biochem Pharmacol. 1977;77:1-124 14389 (...) Antagonism by (+)-amphetamine of the inhibition of [3H]-noradrenaline overflow obtained by alpha-adrenoceptor agonists or bretylium in the perfused cat spleen [proceedings] 43177 1980 04 25 2018 11 13 0007-1188 66 3 1979 Jul British journal of pharmacology Br. J. Pharmacol. Antagonism by (+)-amphetamine of the inhibition of [3H]-noradrenaline overflow obtained by alpha-adrenoceptor agonists or bretylium in the perfused cat spleen [proceedings]. 460P-461P Dubocovich M L ML Langer S Z SZ Moret C

1979 British journal of pharmacology

104. Discrimination between nicotinic receptors in vertebrate ganglia and skeletal muscle by alpha-bungarotoxin and cobra venoms. Full Text available with Trip Pro

Discrimination between nicotinic receptors in vertebrate ganglia and skeletal muscle by alpha-bungarotoxin and cobra venoms. 1. We have used snake neurotoxins, alpha-bungarotoxin and venoms from Naja naja siamensis and Naja nivea, to distinguish the nicotinic receptors of ganglia from those of skeletal neuromuscular junctions. 2. These neurotoxins failed to block responses of isolated guinea-pig longitudinal muscle with adherent myenteric plexus to the nicotinic agonists, nicotine (...) or dimethylphenylpiperazinium, to acetylcholine (ACh), or to electrical field stimulation. 3. The toxins failed to affect responses of the isolated guinea-pig stomach to pregnaglionic stimulation by way of the vagus nerves or of the vas deferens to preganglionic stimulation via the hypogastric nerves. 4. Snake neurotoxins did not block non-adrenergic inhibitory responses of the rabbit small intestine to nicotine or electrical field stimulation. 5. Neurotoxins were ineffective blockers against nicotinic agonists in new-born

1977 The Journal of physiology

105. Blockade of pre-synaptic alpha-adrenoceptors by metiamide [proceedings] Full Text available with Trip Pro

Blockade of pre-synaptic alpha-adrenoceptors by metiamide [proceedings] 31220 1979 02 12 2018 11 13 0007-1188 64 3 1978 Nov British journal of pharmacology Br. J. Pharmacol. Blockade of pre-synaptic alpha-adrenoceptors by metiamide [proceedings]. 416P Griffith O R OR Marshall I I Nasmyth P A PA eng Journal Article England Br J Pharmacol 7502536 0007-1188 0 Adrenergic alpha-Antagonists 3K7670861M Metiamide GYV9AM2QAG Thiourea IM Adrenergic alpha-Antagonists Animals In Vitro Techniques Male

1978 British journal of pharmacology

106. Muscarinic receptor antagonist and an alpha-adrenergic agonist are required in combination to provide stable mydriasis following intravitreal injection in mice Full Text available with Trip Pro

Muscarinic receptor antagonist and an alpha-adrenergic agonist are required in combination to provide stable mydriasis following intravitreal injection in mice Tropicamide (muscarinic receptor antagonist) and phenylephrine (α-adrenergic receptor agonist) are commonly used to dilate the pupils by topical application. These two eye drops are often used, singly or in combination, to dilate the pupil and perform acute light-evoked physiological experiments (electroretinography, for example), before (...) full and stable pupillary dilation following intravitreal injections. Re-instillation of topical mydriatics after intravitreal injections was required for maximal pupillary dilation. A combination of a muscarinic receptor antagonist and an alpha-adrenergic agonist is required for stable mydriasis following intravitreal injection.

2010 Biology and medicine (Aligarh)

107. The alpha(2) adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. (Abstract)

The alpha(2) adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Reduction in the antiparkinsonian benefit of levodopa is a major complication of long-term levodopa treatment in advanced Parkinson's disease (PD). Such loss of benefit arises because of reduced duration of action and appearance of disabling dyskinesia. We assess the potential of the α(2) adrenergic antagonist fipamezole to reduce motor complications in parkinsonian macaques. MPTP (...) to that provided by the higher dose levodopa alone. However, with the combination, antiparkinsonian benefit was of much better quality. The proportion of on time without disabling dyskinesia (79%) was significantly greater than that with high dose levodopa alone (45%). Increased duration and quality of levodopa action may represent therapeutically valuable actions of α(2) adrenergic antagonists.

2010 Movement Disorders

108. DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury

Severe TBI TBI Catecholamines Heart rate variability Adrenergic alpha-Agonists Adrenergic beta-Antagonists Cognitive Impairment Additional relevant MeSH terms: Layout table for MeSH terms Wounds and Injuries Brain Injuries Brain Injuries, Traumatic Hyperkinesis Craniocerebral Trauma Trauma, Nervous System Brain Diseases Central Nervous System Diseases Nervous System Diseases Dyskinesias Neurologic Manifestations Signs and Symptoms Propranolol Clonidine Adrenergic Agents Adrenergic beta-Antagonists (...) Adrenergic Antagonists Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Arrhythmia Agents Antihypertensive Agents Vasodilator Agents Analgesics Sensory System Agents Peripheral Nervous System Agents Sympatholytics Autonomic Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists

2011 Clinical Trials

109. Effects of Adrenergic Drugs on the Fluid Balance During Surgery

System Diseases Pharmaceutical Solutions Phenylephrine Oxymetazoline Adrenergic Agents Esmolol Adrenergic Agonists Cardiotonic Agents Mydriatics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Sympathomimetics Vasoconstrictor Agents Nasal Decongestants Respiratory System Agents Adrenergic alpha-1 Receptor Agonists Adrenergic alpha-Agonists Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Protective Agents Adrenergic beta-1 Receptor Antagonists (...) infusion 0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine Other Name: Drug by Hefeng Pharmaceutical Co, Shanghai, China. Placebo Comparator: Lactated Ringer´s solution 10 ml/h lactated Ringer's solution without active drug was infused intravenously over 3 hours. Drug: Lactated Ringer´s solution Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug Outcome Measures Go to Primary Outcome Measures : Urinary excretion [ Time Frame: 3 hours ] Urine

2011 Clinical Trials

110. Blockade of intra-articular adrenergic receptors increases analgesic demands for pain relief after knee surgery. (Abstract)

examined the expression of opioid peptides and adrenergic receptors in cells infiltrating inflamed synovial tissue and we hypothesized that intra-articular (i.a.) administration of the adrenergic receptor antagonist labetalol will increase postoperative analgesic consumption and/or pain intensity in these patients. In a double-blind, randomized manner, 75 patients undergoing therapeutic knee arthroscopy received i.a. placebo (20 ml saline) or labetalol (2.5 or 5 mg in 20 ml saline) at the end (...) of surgery. Postoperative pain intensity was assessed by visual analog and verbal rating scales at rest and on exertion, and by the consumption of morphine via patient-controlled analgesia. Synovial biopsies were taken during the operation for double-immunofluorescence confocal microscopy studies. Alpha(1)- and beta(2)-adrenergic receptors were co-expressed in opioid peptide-containing cells. No significant difference was seen in pain scores, but patients receiving 2.5 mg labetalol requested

2011 Rheumatology international Controlled trial quality: uncertain

111. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. Full Text available with Trip Pro

Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. To perform a meta-analysis to estimate the intraocular pressure (IOP)-lowering efficacy and safety of alpha(2)-adrenergic agonists (AAs), beta-adrenergic antagonists (BBs), and topical carbonic anhydrase inhibitors (TCAIs) when used in combination with a prostaglandin analog (PGA).MEDLINE, Embase, and the Cochrane Controlled

2010 Archives of ophthalmology

112. Doxazosin an a1 Antagonist for Alcohol Dependence

Alcohol craving Additional relevant MeSH terms: Layout table for MeSH terms Alcoholism Alcohol-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Ethanol Doxazosin Anti-Infective Agents, Local Anti-Infective Agents Central Nervous System Depressants Physiological Effects of Drugs Antihypertensive Agents Adrenergic alpha-1 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms (...) that the noradrenergic (NE) system is involved in the neurobiology of AD, thus representing an interesting new pharmacotherapy target and the theoretical rationale for this proposal. Consistent with the concept that the NE system may represent a new pharmacological target for AD, recent studies have shown that the prototype alpha-1 NE receptor antagonist prazosin reduces alcohol drinking in different animal models. Furthermore, clinical evidence has also confirmed that prazosin appears to be efficacious in reducing

2011 Clinical Trials

116. Canadian guidelines on opioid use disorder among older adults

for opioid withdrawal management? RECOMMENDATION #13: Opioid withdrawal management should only be offered in the context of connection to long-term addiction treatment. [GRADE Quality: Moderate; Strength: Strong] RECOMMENDATION #14: Induction onto an opioid agonist is recommended over a non- opioid treatment withdrawal management in older adults with an OUD. If a trial of tapering is attempted, there should be the option to initiate longer-term opioid agonist therapy or opioid antagonist therapy. [GRADE (...) by the consequences of their drug use (Bachi et al ., 2017) . T he term “opioid” refers to any substance that binds to an opioid receptor . Endogenous opioid peptides (e .g ., endorphins), natural or synthetic exogenous opioid receptor agonists (e .g ., morphine), and opioid receptor antagonists (e .g ., naloxone) are all, by definition, opioids (Inturrisi et al ., 2018) . For the purpose of this guideline, however, the term opioid will be restricted to the description of natural or synthetic exogenous full

2019 CPG Infobase

117. An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL

Adrenergic alpha-Antagonists 5-alpha Reductase Inhibitors Steroid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents (...) An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record

2011 Clinical Trials

118. Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)

relevant MeSH terms: Layout table for MeSH terms Hyperplasia Prostatic Hyperplasia Pathologic Processes Prostatic Diseases Genital Diseases, Male Adrenergic alpha-Antagonists 5-alpha Reductase Inhibitors Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Steroid Synthesis Inhibitors Enzyme Inhibitors Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists (...) Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2011 Clinical Trials

120. Management of Poisoning

as unopposed alpha agonism may worsen accompanying hypertension (pg 57). Grade D, Level 3 D Physostigmine should be considered for treating tachycardia resulting from pure anticholinergic poisoning (pg 58). Grade D, Level 3 Executive summary of key recommendations2 GPP Lidocaine is the drug of choice for most ventricular arrhythmias due to drug toxicity (pg 58). GPP C Sodium bicarbonate should be used in impaired conduction defect caused by sodium channel blocking agents such as tricyclic antidepressants (...) shown improved clinical symptoms with its use (pg 135). Grade D, Level 3 D Chlorpromazine may be considered for suspected serotonin syndrome refractory to standard treatment measures. Chlorpromazine is a serotonin receptor antagonist neuroleptic. Anecdotal case reports have shown improved clinical symptoms with its use (pg 135). Grade D, Level 3 D Dantrolene may be considered for suspected serotonin syndrome refractory to standard treatment measures. Dantrolene relaxes skeletal muscles and prevents

2020 Ministry of Health, Singapore

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>